Evidence map›Paper›PMID 41168805›Full record

ReviewTranslational neurodegeneration2025

Roles of TREM2 in Alzheimer's disease.

Xiaoshan Qi, Kedong Zhu, Wei Ke, Junjie Wang, Shanping Mao, Guiqin Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Translational neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaoshan QiDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Kedong ZhuDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Wei KeDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Junjie WangSchool of Physical Education, China University of Geosciences, Wuhan, 430074, China. wangjunjie@cug.edu.cn.
Shanping MaoDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. mspzy@163.com.
Guiqin ChenDepartment of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. chenguiqin@whu.edu.cn.ORCID http://orcid.org/0009-0000-9116-1296

Funding

the Hubei Provincial Natural Science Foundation of China JCZRQN202501239the National Natural Science Foundation of China NO. 82471439
6 · The paper itself

Abstract

Variants in the triggering receptor expressed on myeloid cells 2 (TREM2) gene have been demonstrated to increase the risk of late-onset Alzheimer's disease (AD) and Nasu-Hakola disease. As a type I transmembrane receptor, TREM2 is predominantly expressed in microglia within the central nervous system. Extensive research over the past decade has consistently established the critical role of TREM2 in AD pathogenesis, encompassing its regulation of microglial inflammatory responses, amyloid-β deposition, and tau pathology. Notably, the soluble TREM2 fragment (sTREM2) is emerging as a promising candidate biomarker for clinical progression of AD, as evidenced by human studies. Despite these advances, the precise roles of membrane-bound TREM2 and sTREM2 in AD pathogenesis remain incompletely elucidated. Novel mouse models and technological innovations have enabled therapeutic approaches targeting TREM2 for neuroprotection. This review summarizes this progress and highlights areas for future research towards the development of TREM2-directed therapeutics.

Indexed as

Alzheimer DiseaseMembrane GlycoproteinsReceptors, ImmunologicAnimalsBiomarkersHumansMicrogliaBiomarkersMembrane GlycoproteinsReceptors, ImmunologicTREM2 protein, humanAlzheimer’s diseaseAmyloidMicrogliaSoluble TREM2TauTherapeutic prospectsTREM2Variants

Identifiers

PMID41168805
PMCPMC12577446

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.